Biohaven Pharmaceutical Holding Company Ltd. has finished its enrollment in the clinical study for trigriluzole for individuals with spinocerebellar ataxia (SCA), a rare neurodegenerative disorder.
"The completion of enrollment in this trial represents an important milestone for our glutamate modulating program in neurologic illnesses," Biohave CEO Vlad Coric said.
The rarity of SCA means that, like many other less common disorders, medications and solutions have been hard to find in the past.
"We are acutely aware of the high unmet medical need in SCA, and if the results of the trial are positive, we expect to submit a new drug application to the FDA in early 2018," Coric said.
SCA affects 22,000 Americans. There are no approved medications for the treatment of the disorder.
Until now, Trigriluzole has been given Orphan Drug Designation and Fast Track Designation by the U.S. Food and Drug Administration.